AMAL Therapeutics SA

A bevy of big venture capital financings have been announced since Labor Day, the official end of summer in the US, led by a $300m series C round for Acelyrin, Inc. The boom in VC mega-deals is rema

Boehringer Ingelheim GmbH is making much of its R&D pipeline but a few old products are continuing to keep the company's coffers topped up to pay for that research. The family-owned German company re

Boehringer Ingelheim GmbH is the latest pharmaceutical company to identify receptor tyrosine kinase-like orphan receptor 1 (ROR1) as a viable target to treat cancer by splashing out €1.18bn to acquir

In an interview with Scrip , Boehringer Ingelheim International GmbH ’s top business development executives offered their views on conducting transactions amid a pandemic, why a company usually focus